Head-to-head · Cost-Efficiency Index
Somi Health vs Aquivia Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Somi Health
Shoppers comfortable committing to a 3-month plan to unlock the lower blended monthly rate.
Visit Somi HealthAquivia Health
Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Visit Aquivia HealthThe verdict
Somi Health and Aquivia Health tie on the Cost-Efficiency Index at 62/100, so neither wins outright on the numbers. For most shoppers we'd start with Somi Health (ranked #212, a hair above #217) — Shoppers comfortable committing to a 3-month plan to unlock the lower blended monthly rate. But Aquivia Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Somi Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Somi Health | Aquivia Health |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 62/100 |
| Semaglutide / mo | $135/mo (compounded) | $149/mo |
| Tirzepatide / mo | $165/mo (3-month plan, compounded) | $179/mo |
| Semaglutide / yr (modeled) | $1,620 | $1,788 |
| Tirzepatide / yr (modeled) | $1,980 | $2,148 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #212 | #217 |
Somi Health
62/100Where the value is
- Offers an oral semaglutide tablet option in addition to injections, a differentiator versus most peers
- Displays a LegitScript 'Approved' seal
- Discloses it uses 503A state-licensed pharmacies (category-level transparency)
The tradeoffs
- 'Starting at' injection prices are 3-month prepay rates, not real monthly cash prices
- The correct domain (joinsomi.com) is easy to confuse with the abandoned somihealth.com, a parked/for-sale domain
Aquivia Health
62/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.